HPR45 Impact of Nilotinib Reimbursement Coverage on the Use of Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) in Chinese Tertiary Care Hospitals: A Retrospective Analysis
Abstract
Authors
Y Zhang W Chen Y Xu A Pathak Y Lu D Yang Y Zhai